Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Diabetes & Metabolic Disorders
Published in: Journal of Diabetes & Metabolic Disorders 1/2019

01-06-2019 | Obesity | Research Article

Serum miR-17 levels are downregulated in obese, African American women with elevated HbA1c

Authors: Ariel Williams, Dara Mc Dougal, Willysha Jenkins, Natasha Greene, Clarlynda Williams-DeVane, K. Sean Kimbro

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2019

Login to get access

Abstract

Purpose

Type 2 diabetes is heterogeneous disease characterized by several conditions including hyperglycemia. It is estimated that over 350 million people worldwide are suffering from type 2 diabetes and this number is expected to rise. According to the CDC, African Americans were observed to have a 40% higher incidence of diabetes compared to European Americans. Epigenetic modulating mechanisms such as microRNAs (miRNAs), have recently been established as a massive regulatory machine in metabolic syndrome, obesity and type 2 diabetes. In the present study, we aimed to investigate the serum levels of circulating miRNA 17 (miR-17) of obese, African American women with elevated HbA1c.

Methods

We investigated miR-17 serum levels using qPCR. Then we used Pairwise Pearson Correlation Test to determine the relationship between clinical metabolic parameters and miR-17 serum levels.

Results

The results indicated that participants with elevated HbA1c exhibited a down regulation of serum miR-17 levels compared to participants with normal HbA1c. MiR-17 was also correlated with serum calcium in participants with normal HbA1c.

Conclusions

The results suggest that serum miR-17 is involved in the regulation of glucose and calcium homeostasis, which may contribute to the development of type 2 diabetes.
Literature
1.
Mita T, Goto H, Azuma K, Jin W, Nomiyama Y, et al. Impact of insulin resistance on enhanced monocyte adhesion to endothelial cells and atherosclerogenesis independent of LDL cholesterol level. BBRC. 2010;395:477–83.PubMed
2.
Wu L, Dai X, Zhang H, Zeng S, Xi W. Profiling peripheral microRNAs in obesity and type 2 diabetes mellitus. APMIS. 2015;123:580–5.CrossRefPubMed
3.
Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311–21.CrossRefPubMed
4.
5.
6.
Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307:491–7.CrossRefPubMed
7.
Staiano AE, Harrington DM, Johannisen NM, Newton RL, Sarzynski MA, et al. Uncovering physiological mechanisms for health disparities in type 2 diabetes. Ethn Dis. 2015;25:31–7.PubMedPubMedCentral
8.
Carnethon MR, Palaniappan LP, Burchfiel CM, Brancati FL, Fortmann SP. Serum insulin, obesity, and the incidence of type 2 diabetes in black and white adults the atherosclerosis risk in communities’ study, 1987–1998. Diabetes Care. 2002;25:1358–64.CrossRefPubMedPubMedCentral
9.
Feil R. Environmental and nutritional effects on the epigenetic regulation of genes. Mutat Res. 2006;600:46–57.CrossRefPubMed
10.
Junien C. Impact of diets and nutrients/ drugs on early epigenetic programming. J Inherit Metab Dis. 2006;29:359–65.CrossRefPubMed
11.
Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol. 2013;9:513–21.CrossRefPubMed
12.
13.
Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci. 2011;108:5003–8.CrossRefPubMed
14.
Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol. 2009;11:1143–9.CrossRefPubMed
15.
Vickers KC, Palmisano B, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13:423–33.CrossRefPubMedPubMedCentral
16.
He Y, Ding Y, Liang B, Lin J, Kim Kim T.K., Yu H., Hang H., Wang K. (2017) A systematic study of dysregulated microRNA in type 2 diabetes mellitus. Int J Mol Sci 18:456.
17.
Deiuliis JA. MicroRNAa as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. Int J Obes. 2016;40:88–101.CrossRef
18.
Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on it genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013;220:1603–14.CrossRef
19.
Zhang C, Qian D, Zhao H, Yu P, Sun Z. Mir17 improves insulin sensitivity through inhibiting serum levels of ASK-1 and anti-inflammation of macrophages. Biomed Pharmacother. 2018;100:448–54.CrossRefPubMed
20.
Kroh EM, Parkin RK, Mitchell P, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRTPCR). Methods. 2010;50:298–301.CrossRefPubMedPubMedCentral
21.
22.
Simpson K, Wonnacott A, Fraser DJ, Bowen T. MicroRNAs in diabetic nephropathy: from biomarkers to therapy. Curr Diabetes Rep. 2016;16:35.CrossRef
23.
24.
Price NL, Ramirez CM, Fernandez-Hernando C. Relevance of microRNA in metabolic diseases. Crit Rev Clin Lab Sci. 2014;51:305–20.CrossRefPubMed
25.
Chen H, Lan HY, Roukos DH, Cho WC. Application of microRNAs in diabetes mellitus. J Endocrinol. 2014;222:1–10.CrossRef
26.
27.
Guay C, Roggli E, Nesca V, Jacovetti C, Regazzi R. Diabetes mellitus, a microRNA-related disease? Transl Res. 2011;157:253–64.CrossRefPubMed
28.
Nagareddy PR, Kraakman M, Masters SL, Stirzaker RA, Gorman DJ, Grant RW, et al. Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab. 2014;19:821–35.CrossRefPubMedPubMedCentral
29.
Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik (1993) A tumor necrosis factor- alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268:26055–26058.
30.
Vatner DF, Majumdar SK, Kumashiro N, Petersen MC, Rahimi Y, Gattu AK, et al. Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids. Proc Natl Acad Sci. 2015;112:1143–8.CrossRefPubMed
31.
Cai D, Yuan M, Frantz D, Melendez P, Hansen L, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11:183–90.CrossRefPubMedPubMedCentral
32.
Ferreira D, Simao A, Rodrigues C, Castro R. Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. FEBS J. 2014;281:2503–24.CrossRefPubMed
33.
34.
Thaler J, Yi C, Schur E, Guyenet S, Hwang B, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest. 2012;122:153–62.CrossRefPubMed
35.
Kloting N, Berthold S, Kovacs P, Schon M, Fasshauer M, et al. MicroRNA serum levels in human omental and subcutaneous adipose tissue. PLoS One. 2009;4:e4699.CrossRefPubMedPubMedCentral
36.
Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107:677–84.CrossRefPubMed
37.
Heneghan H, Miller N, McAnena O, O’Brien T, Kerin M. Differential miRNA serum levels in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. J Clin Endocrinol Metab. 2011;96:E846–50.CrossRefPubMed
38.
Hulsmans M, Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc Res. 2013;100:7–18.CrossRefPubMed
39.
Levy J, Gavin IIIJ, Sowers J. Diabetes mellitus: a disease of abnormal cellular calcium metabolism? Am J Med. 1994;96:260–73.CrossRefPubMed
40.
Roe M, Philipson L, Frangakis C, Kuznestov A, Mertz R, et al. Defective glucose-dependent endoplasmic reticulum Ca2+ sequestration in diabetic mouse islets of Langerhans. J Biol Chem. 1994;269:279–82.
41.
Janicki P, Horn J, Singh G, Franks W, Franks J. Diminished brain synaptic plasma membrane Ca2+-ATPase activity in rats with streptozocin-induced diabetes: association with reduced anesthetic requirements. Life Sci. 1994;55:359–64.CrossRef
42.
Tomizawa H, Yamazaki M, Kunika K, Itakura M, Yamashita K. Association of elastin glycation and calcium deposit in diabetic rat aorta. Diab Res Clin Pract. 1993;19:1–8.CrossRef
43.
Kern T, Kowluru R, Engerman R. Abnormalities of retinal metabolism in diabetes or galactosemia: ATPase and glutathione. Invest Ophthalmol Vis Sci. 1994;35:2962–7.PubMed
44.
Levy J, Zhu Z, Dunbar J. The effect of glucose and calcium on CA2+-ATPase in pancreatic islets isolated from normal and NIDDM rat models. Metabolism. 1998;47:185–9.CrossRefPubMed
45.
46.
Juntti-Berggren L, Larson O, Rorsman P, Ammala C, Bokvist K, et al. Increased activity of L-type Ca2+ channels exposed to serum from patients with type 1 diabetes. Science. 1993;261:86–90.CrossRefPubMed
47.
Hellman B, Gylfe E, Bergsten P, Grapengiesse E, Lund P, et al. Glucose induces oscillatory Ca2+ signaling and insulin release in human pancreatic beta cells. Diabetologia. 1994;37(Suppl 2):S11–20.CrossRefPubMed
48.
Cheng Y, Wright C, Kirschner M, Williams M, Sarin K, et al. KCa1.1, a calcium activated potassium channel subunit alpha 1, is targeted by mir-17-5p and modulates cell migration in malignant pleural mesothelioma. Mol Cancer. 2016;15:44.CrossRefPubMedPubMedCentral
49.
Jioa H, Arner P, Hoffstedt J, Brodin D, Dubern B, et al. Genome wide association study identifies KCNMA1 contributing to human obesity. BMC Med Genet. 2011;4:51.
50.
Gallant K, Speiegel D. Calcium balance in chronic kidney disease. Curr Osteoporos Rep. 2017;15:214–21.CrossRef
51.
Mima A. Diabetic nephropathy: protective factors and a new therapeutic paradigm. J Diabetes Complicat. 2013;27:526–30.CrossRefPubMed
52.
Izreig S, Ssamborska B, Johnson R, Artyomov M, Duchaine T, Jones R. The miR-17~92 microRNA cluster is a global regulator of tumor metabolism. Cell Rep. 2016;16:1915–28.CrossRefPubMed
53.
Liu Y, Liu W, Hu C, Xue Z, Wang G, Dang B, et al. MiR-17 modulates osteogenic differentiation through a coherent feed-forward loop in mesenchymal stem cells isolated from periodontal ligaments of patients with periodontitis. Stem Cells. 2011;29:1804–16.CrossRefPubMed
Metadata
Title
Serum miR-17 levels are downregulated in obese, African American women with elevated HbA1c
Authors
Ariel Williams
Dara Mc Dougal
Willysha Jenkins
Natasha Greene
Clarlynda Williams-DeVane
K. Sean Kimbro
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2019
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-019-00404-3

Other articles of this Issue 1/2019

Journal of Diabetes & Metabolic Disorders 1/2019 Go to the issue

Research Article

Factors influencing diabetes self-care practice among type 2 diabetes patients attending diabetic care follow up at an Ethiopian General Hospital, 2018

Research article

Minocycline attenuates the development of diabetic neuropathy by modulating DREAM and BDNF protein expression in rat spinal cord

Research Article

Evaluating the impact of an insulin pump discontinuation action plan on patient or caregiver confidence and anxiety

Research Article

Gestational diabetes mellitus in association with macrosomia in Iran: a meta-analysis

Research Article

In vivo studies demonstrate that endothelin-1 traps are a potential therapy for type I diabetes

Research article

Impact of alexithymia on glycemic control among Lebanese adults with type 2 diabetes

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits